+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 80Years
All Genders
ID05477927

Study of Dual-Targeted VEGFR1 and PD-L1 CAR-T Cells for Treating Solid Tumor Metastases in Pleural, Peritoneal, or Leptomeningeal Sites

Led by Sichuan University · Updated on 2026-08-13

40

Participants Needed

1

Research Sites

78 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and early antitumor effects of dual-targeting VEGFR1PD-L1 chimeric antigen receptor CAR T-cells in adults with solid tumors that have spread to the pleural, peritoneal, or leptomeningeal areas. These metastases have very poor outlooks due to their unique immune environment and physical barriers, limiting treatment options. This Phase I open-label study uses a dose-escalation and expansion design to find the best dose and assess initial effects of this novel approach. Participants receive a single infusion of their own genetically modified T-cells targeting VEGFR1 and PD-L1. Administration routes depend on the metastatic site intrapleural or intraperitoneal for pleural or peritoneal metastases, and intrathecal for leptomeningeal metastases. The study includes two cohorts with different dosing strategies and escalation designs. After determining the recommended phase II dose RP2D, an expansion phase will further assess safety and preliminary efficacy. During the study, participants are monitored for dose-limiting toxicities and adverse events up to six months after infusion. The research team evaluates tumor response, progression-free survival, overall survival, and CAR-T cell persistence in blood and local fluids. Neurological symptoms and tumor cell clearance in cerebrospinal fluid are also assessed. Participation includes clinical evaluations, laboratory tests, and follow-up visits for up to five years to track long-term outcomes.

CONDITIONS

Brief Title

Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases

Research Team

X

XIA HE, Ph.D

G

Ge Gao, Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here